Wexford Capital’s Structure Therapeutics GPCR Stock Holding History

Wexford Capital’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$661K	Sell	13,709 -1,126	-8%	-$77.1K	0.1%	70
2025 Q4	$1.03M	Buy	+14,835	New	+$606K	0.2%	75
2025 Q2	–	Sell	-30,102	Closed	-$521K	–	278
2025 Q1	$521K	Sell	30,102 -51,770	-63%	-$1.27M	0.14%	113
2024 Q4	$2.22M	Sell	81,872 -16,351	-17%	-$580K	0.35%	41
2024 Q3	$4.31M	Buy	98,223 +5,000	+5%	+$193K	1.03%	25
2024 Q2	$3.66M	Buy	93,223 +60,761	+187%	+$2.49M	0.93%	24
2024 Q1	$1.39M	Hold	32,462	–	–	0.28%	67
2023 Q4	$1.32M	Sell	32,462 -35,516	-52%	-$2.04M	0.28%	63
2023 Q3	$3.43M	Buy	+67,978	New	+$2.19M	0.76%	33

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wexford Capital's GPCR Position: Q1 2026 in Review

Wexford Capital reduced its Structure Therapeutics (GPCR) stake by 7.6% in Q1 2026, selling an estimated $77.1K and leaving 13,709 shares worth $661K. The position accounts for 0.1% of the portfolio, ranked #70.

Wexford Capital first reported a position in GPCR in Q3 2023 and has held it in 9 quarters since. The position peaked at $4.31M in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Wexford Capital held 13,709 shares of Structure Therapeutics worth $661K as of Q1 2026.
Wexford Capital sold 1,126 Structure Therapeutics shares in Q1 2026, an estimated $77.1K.
Structure Therapeutics made up 0.1% of Wexford Capital's portfolio in Q1 2026, its #70 holding.
Wexford Capital first reported a position in Structure Therapeutics in Q3 2023 and has held it in 9 quarters since.
Wexford Capital's Structure Therapeutics position peaked at $4.31M in Q3 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Wexford Capital's 13F filing for Q1 2026, filed 15 May 2026.